HRP20130982T1 - Roflumilast za lijeäśenje pulmonalne hipertenzije - Google Patents
Roflumilast za lijeäśenje pulmonalne hipertenzije Download PDFInfo
- Publication number
- HRP20130982T1 HRP20130982T1 HRP20130982TT HRP20130982T HRP20130982T1 HR P20130982 T1 HRP20130982 T1 HR P20130982T1 HR P20130982T T HRP20130982T T HR P20130982TT HR P20130982 T HRP20130982 T HR P20130982T HR P20130982 T1 HRP20130982 T1 HR P20130982T1
- Authority
- HR
- Croatia
- Prior art keywords
- pulmonary
- hypertension
- arterial hypertension
- pulmonary arterial
- roflumilast
- Prior art date
Links
- 208000002815 pulmonary hypertension Diseases 0.000 title claims 12
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 title claims 6
- 229960002586 roflumilast Drugs 0.000 title claims 6
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 5
- PCGSQNPMMSALEJ-UHFFFAOYSA-N roflumilast n-oxide Chemical compound ClC1=C[N+]([O-])=CC(Cl)=C1NC(=O)C1=CC=C(OC(F)F)C(OCC2CC2)=C1 PCGSQNPMMSALEJ-UHFFFAOYSA-N 0.000 claims 5
- 206010021143 Hypoxia Diseases 0.000 claims 4
- 230000007954 hypoxia Effects 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 208000027932 Collagen disease Diseases 0.000 claims 3
- 206010010356 Congenital anomaly Diseases 0.000 claims 3
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 claims 3
- 208000015872 Gaucher disease Diseases 0.000 claims 3
- 208000031886 HIV Infections Diseases 0.000 claims 3
- 208000037357 HIV infectious disease Diseases 0.000 claims 3
- 208000031953 Hereditary hemorrhagic telangiectasia Diseases 0.000 claims 3
- 208000021124 Heritable pulmonary arterial hypertension Diseases 0.000 claims 3
- 208000020875 Idiopathic pulmonary arterial hypertension Diseases 0.000 claims 3
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 3
- 208000024799 Thyroid disease Diseases 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 208000007345 glycogen storage disease Diseases 0.000 claims 3
- 208000034737 hemoglobinopathy Diseases 0.000 claims 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 3
- 208000018337 inherited hemoglobinopathy Diseases 0.000 claims 3
- 208000007232 portal hypertension Diseases 0.000 claims 3
- 238000010911 splenectomy Methods 0.000 claims 3
- 239000003053 toxin Substances 0.000 claims 3
- 231100000765 toxin Toxicity 0.000 claims 3
- 108700012359 toxins Proteins 0.000 claims 3
- 230000002792 vascular Effects 0.000 claims 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 2
- 208000031467 Pulmonary capillary hemangiomatosis Diseases 0.000 claims 2
- 208000014777 Pulmonary venoocclusive disease Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 208000000122 hyperventilation Diseases 0.000 claims 2
- 230000000870 hyperventilation Effects 0.000 claims 2
- 210000001147 pulmonary artery Anatomy 0.000 claims 2
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 2
- 230000009424 thromboembolic effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Claims (12)
1. Uporaba, naznačena time, da se spoj odabran iz skupine koja sadrži roflumilast, farmaceutski prihvatljivu sol od roflumilasta, roflumilast-N-oksid i farmaceutski prihvatljivu sol od roflumilast-N-oksida, upotrebljava za proizvodnju farmaceutskog sastava za preventivno liječenje pulmonalne hipertenzije.
2. Uporaba prema zahtjevu 1, naznačena time, da je spoj odabran iz skupine koja sadrži roflumilast i farmaceutski prihvatljivu sol od roflumilasta.
3. Uporaba prema zahtjevu 1, naznačena time, da je spoj odabran iz skupine koja sadrži roflumilast-N-oksid i farmaceutski prihvatljivu sol od roflumilast-N-oksida.
4. Uporaba prema zahtjevu 1, naznačena time, da spoj je roflumilast.
5. Uporaba prema zahtjevu 1, naznačena time, da spoj je roflumilast-N-oksid.
6. Uporaba prema bilo kojem od zahtjeva 1 do 5, naznačena time, da se pulmonalna hipertenzija odnosi na oblik pulmonalne hipertenzije, koji je odabran iz skupine koju čine idiopatska pulmonalna arterijska hipertenzija; obiteljska pulmonalna arterijska hipertenzija; pulmonalna arterijska hipertenzija povezana s vaskularnom kolagenozom, urođenim sistemsko-pulmonalnim račvanjima, portalnom hipertenzijom, HIV-infekcijom, drogama ili toksinima; pulmonalna arterijska hipertenzija povezana s tiroidnim poremećajima, poremećajem skladištenja glikogena, Gaucherovom bolešću, nasljednom hemoragijskom teleangiektazijom, hemoglobinopatijama, mijeloproliferativnim poremećajima ili splenektomijom; pulmonalna arterijska hipertenzija povezana s pulmonalno-kapilarnom hemangiomatozom; trajna pulmonalna arterijska hipertenzija kod novorođenčadi; pulmonalna arterijska hipertenzija povezana s kroničnom opstrukcijskom bolešću dišnih putova, intersticijalnom plućnom bolešću, hipoksijom izazvanim poremećajima alveolarne hiperventilacije, hipoksijom izazvanim poremećajima disanja kod spavanja ili kroničnim izlaganjem visokim nadmorskim visinama; pulmonalna arterijska hipertenzija povezana s nenormalnim razvojem; te pulmonalna arterijska hipertenzija uzrokovana tromboemboličkom opstrukcijom distalnih pulmonalnih arterija.
7. Uporaba prema bilo kojem od zahtjeva 1 do 5, naznačena time, da se pulmonalna hipertenzija odnosi na oblik pulmonalne hipertenzije, koji je odabran iz skupine koju čine idiopatska pulmonalna arterijska hipertenzija; obiteljska pulmonalna arterijska hipertenzija; pulmonalna arterijska hipertenzija povezana s vaskularnom kolagenozom, urođenim sistemsko-pulmonalnim račvanjima, portalnom hipertenzijom, HIV-infekcijom, drogama ili toksinima; pulmonalna arterijska hipertenzija povezana s tiroidnim poremećajima, poremećajem skladištenja glikogena, Gaucherovom bolešću, nasljednom hemoragijskom teleangiektazijom, hemoglobinopatijama, mijeloproliferativnim poremećajima ili splenektomijom; pulmonalna arterijska hipertenzija povezana s pulmonalno-kapilarnom hemangiomatozom; trajna pulmonalna arterijska hipertenzija kod novorođenčadi; pulmonalna arterijska hipertenzija povezana s intersticijalnom plućnom bolešću, hipoksijom izazvanim poremećajima alveolarne hiperventilacije, hipoksijom izazvanim poremećajima disanja kod spavanja ili kroničnim izlaganjem visokim nadmorskim visinama; pulmonalna arterijska hipertenzija povezana s nenormalnim razvojem; te pulmonalna arterijska hipertenzija uzrokovana tromboemboličkom opstrukcijom distalnih pulmonalnih arterija.
8. Uporaba prema jednom od zahtjeva 6 ili 7, naznačena time, da se pulmonalna hipertenzija odnosi na idiopatsku pulmonalnu arterijsku hipertenziju.
9. Uporaba prema jednom od zahtjeva 6 ili 7, naznačena time, da se pulmonalna hipertenzija odnosi na obiteljsku pulmonalnu arterijsku hipertenziju.
10. Uporaba prema zahtjevu 6, naznačena time, da se pulmonalna hipertenzija odnosi na pulmonalnu hipertenziju koja je povezana s kroničnom opstrukcijskom plućnom bolešću.
11. Uporaba prema jednom od zahtjeva 6 ili 7, naznačena time, da se pulmonalna hipertenzija odnosi na pulmonalnu arterijsku hipertenziju koja je povezana s vaskularnom kolagenozom, urođenim sistemsko-pulmonalnim račvanjima, portalnom hipertenzijom, HIV-infekcijom, drogama ili toksinima.
12. Uporaba prema jednom od zahtjeva 6 ili 7, naznačena time, da se pulmonalna hipertenzija odnosi na pulmonalnu arterijsku hipertenziju koja je povezana s tiroidnim poremećajima, poremećajem skladištenja glikogena, Gaucherovom bolešću, nasljednom hemoragijskom teleangiektazijom, hemoglobinopatijama, mijeloproliferativnim poremećajima ili splenektomijom.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05103147 | 2005-04-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20130982T1 true HRP20130982T1 (hr) | 2013-11-22 |
Family
ID=34939388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20130982TT HRP20130982T1 (hr) | 2005-04-19 | 2013-10-16 | Roflumilast za lijeäśenje pulmonalne hipertenzije |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8648100B2 (hr) |
| EP (2) | EP1874309A1 (hr) |
| JP (2) | JP2008536888A (hr) |
| KR (1) | KR101358479B1 (hr) |
| CN (2) | CN102614176A (hr) |
| AU (1) | AU2006237300B2 (hr) |
| BR (1) | BRPI0610498A2 (hr) |
| CA (1) | CA2604295C (hr) |
| CY (1) | CY1114468T1 (hr) |
| DK (1) | DK2366393T3 (hr) |
| EA (1) | EA016037B1 (hr) |
| ES (1) | ES2433661T3 (hr) |
| HR (1) | HRP20130982T1 (hr) |
| IL (2) | IL186538A0 (hr) |
| ME (1) | ME01609B (hr) |
| MX (1) | MX2007012711A (hr) |
| NO (1) | NO20075662L (hr) |
| NZ (1) | NZ561746A (hr) |
| PL (1) | PL2366393T3 (hr) |
| PT (1) | PT2366393E (hr) |
| RS (1) | RS52944B (hr) |
| SI (1) | SI2366393T1 (hr) |
| WO (1) | WO2006111495A1 (hr) |
| ZA (1) | ZA200707930B (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009013286A1 (en) * | 2007-07-24 | 2009-01-29 | Novartis Ag | Organic compounds |
| WO2009115235A1 (en) * | 2008-03-20 | 2009-09-24 | Bayer Schering Pharma Aktiengesellschaft | Pde inhibitors for the treatment of pulmonary hypertension |
| KR102154104B1 (ko) | 2013-01-28 | 2020-09-09 | 인코젠 쎄라퓨틱스 프라이빗 리미티드 | 로플루밀라스트 n- 옥사이드의 흡입에 의한 자가면역, 호흡 및 염증성 장애의 치료방법 |
| WO2015089105A1 (en) | 2013-12-09 | 2015-06-18 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
| CN107038965A (zh) * | 2017-05-05 | 2017-08-11 | 深圳浩翔光电技术有限公司 | Led显示装置、成型模组、及其生产工艺 |
| KR20190005708A (ko) | 2017-07-05 | 2019-01-16 | 이화여자대학교 산학협력단 | 에피디티오디옥소피페라진 화합물 또는 이의 유도체, 또는 이들의 약학적으로 허용가능한 염을 포함하는 폐동맥고혈압 예방 또는 치료용 약학적 조성물 |
| CN115969847A (zh) * | 2023-02-03 | 2023-04-18 | 华中科技大学 | 罗氟司特在制备治疗心力衰竭的药物中的应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB371800A (en) | 1929-10-21 | 1932-04-28 | Willem Zaadnoordijk | A process of filtering gases and fogs |
| GB343664A (en) | 1929-12-27 | 1931-02-26 | William Duncan Grant | Subaquatic rock drilling devices |
| GB357903A (en) | 1931-01-05 | 1931-10-01 | Oskar Rosenfelder | Improvements in catamenial appliances and infants' diapers |
| GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
| AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
| ES2176252T3 (es) | 1993-07-02 | 2002-12-01 | Altana Pharma Ag | Benzamidas sustituidas con fluoro-alcoxi y su utilizacion como agentes inhibidores de fosfodiesterasas de nucleotidos ciclicos. |
| US5728705A (en) | 1993-10-04 | 1998-03-17 | The Trustees Of Columbia University In The City Of New York | Method of inducing vasorelaxation to treat pulmonary hypertension |
| GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
| US6331543B1 (en) * | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
| US6333354B1 (en) * | 1997-02-28 | 2001-12-25 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Synergistic combination of PDE inhibitors and adenylate cyclase agonists or guanyl cyclyse agonists |
| WO1998049166A1 (en) | 1997-04-25 | 1998-11-05 | Pfizer Limited | PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION |
| FR2762841B1 (fr) * | 1997-04-30 | 1999-07-02 | Jouveinal Inst Rech | Diazepino-indolones inhibitrices de phosphodiesterases iv |
| EP1049695B1 (de) | 1997-11-12 | 2002-02-13 | Bayer Ag | 2-phenyl-substituierte imidazotriazinone als phosphodiesterase inhibitoren |
| ATE247117T1 (de) | 1998-04-20 | 2003-08-15 | Pfizer | Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen |
| DE19819023A1 (de) | 1998-04-29 | 1999-11-04 | Merck Patent Gmbh | Thienopyrimidine |
| TWI223598B (en) | 1998-06-22 | 2004-11-11 | Pfizer Ireland Pharmaceuticals | An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate |
| KR100353014B1 (ko) | 1998-11-11 | 2002-09-18 | 동아제약 주식회사 | 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물 |
| ID30182A (id) | 1999-03-22 | 2001-11-08 | Bristol Myers Squibb Co | PENGHAMBAT-PENGHAMBAT PIRIDOPIRIDAZINA LEBURAN DARI cGMP FOSFODIESTERASE |
| EP1219609B1 (en) | 1999-09-16 | 2007-04-04 | Tanabe Seiyaku Co., Ltd. | Aromatic nitrogenous six-membered ring compounds |
| TW200400821A (en) | 1999-11-02 | 2004-01-16 | Pfizer | Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient |
| US6821978B2 (en) | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
| MXPA03006885A (es) * | 2001-01-31 | 2003-11-13 | Pfizer Prod Inc | Derivados de eteres utiles como agentes inhibidores de las isozimas pde4. |
| JP2004518691A (ja) * | 2001-01-31 | 2004-06-24 | ファイザー・プロダクツ・インク | Ｐｄｅ４アイソザイムの阻害剤として有効なチアゾリル−、オキサゾリル−、ピロリル−、イミダゾリル−酸アミド誘導体 |
| US7013084B2 (en) * | 2001-02-28 | 2006-03-14 | Lambda Opticalsystems Corporation | Multi-tiered control architecture for adaptive optical networks, and methods and apparatus therefor |
| DE10135815A1 (de) | 2001-07-23 | 2003-02-06 | Bayer Ag | Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen |
| ATE335486T1 (de) * | 2001-11-05 | 2006-09-15 | Merck Patent Gmbh | Hydrazono-malonitrile |
| MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
| US20040087653A1 (en) * | 2002-05-16 | 2004-05-06 | Manning Pamela T. | Methods for the treatment of respiratory diseases and conditions with a selective iNOS inhibitor and a PDE inhibitor and compositions therefor |
| WO2004072079A1 (en) | 2003-02-11 | 2004-08-26 | Pfizer Limited | Hydrated and anhydrous sildenafil hemi-citrate compound |
| US20060239927A1 (en) * | 2003-03-31 | 2006-10-26 | Kyowa Hakko Kogyo Co., | Drug for airway administration |
| MXPA05012302A (es) * | 2003-05-22 | 2006-01-30 | Altana Pharma Ag | Composicion que comprende un inhibidor de pde4 y un inhibidor de pde5. |
| WO2004105751A1 (en) | 2003-05-28 | 2004-12-09 | Glaxo Group Limited | Traitement of cardiovascular pathology |
| GB0317498D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Compounds |
| US7153870B2 (en) * | 2003-07-25 | 2006-12-26 | Pfizer Inc. | Nicotinamide derivatives useful as PDE4 inhibitors |
| US7132435B2 (en) * | 2003-07-25 | 2006-11-07 | Pfizer Inc. | Compounds |
| JP2007503393A (ja) * | 2003-08-22 | 2007-02-22 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | Ｃｏｐｄ及び肺高血圧の治療方法 |
| MXPA06012279A (es) | 2004-04-23 | 2007-01-31 | Celgene Corp | Metodos de uso y composiciones que comprenden moduladores de pde4 para el tratamiento y manejo de la hipertension pulmonar. |
-
2006
- 2006-04-12 CN CN2012100507411A patent/CN102614176A/zh active Pending
- 2006-04-12 KR KR1020077026282A patent/KR101358479B1/ko not_active IP Right Cessation
- 2006-04-12 MX MX2007012711A patent/MX2007012711A/es active IP Right Grant
- 2006-04-12 RS RS20130378A patent/RS52944B/en unknown
- 2006-04-12 ME MEP-2013-129A patent/ME01609B/me unknown
- 2006-04-12 CN CNA2006800130225A patent/CN101163476A/zh active Pending
- 2006-04-12 EP EP06725734A patent/EP1874309A1/en not_active Withdrawn
- 2006-04-12 US US11/918,397 patent/US8648100B2/en not_active Expired - Fee Related
- 2006-04-12 AU AU2006237300A patent/AU2006237300B2/en not_active Ceased
- 2006-04-12 PL PL11168764T patent/PL2366393T3/pl unknown
- 2006-04-12 WO PCT/EP2006/061557 patent/WO2006111495A1/en active Application Filing
- 2006-04-12 NZ NZ561746A patent/NZ561746A/en not_active IP Right Cessation
- 2006-04-12 EA EA200702201A patent/EA016037B1/ru not_active IP Right Cessation
- 2006-04-12 BR BRPI0610498-3A patent/BRPI0610498A2/pt not_active IP Right Cessation
- 2006-04-12 JP JP2008507056A patent/JP2008536888A/ja active Pending
- 2006-04-12 DK DK11168764.6T patent/DK2366393T3/da active
- 2006-04-12 EP EP11168764.6A patent/EP2366393B1/en active Active
- 2006-04-12 ES ES11168764T patent/ES2433661T3/es active Active
- 2006-04-12 PT PT111687646T patent/PT2366393E/pt unknown
- 2006-04-12 SI SI200631678T patent/SI2366393T1/sl unknown
- 2006-04-12 CA CA2604295A patent/CA2604295C/en not_active Expired - Fee Related
-
2007
- 2007-09-17 ZA ZA200707930A patent/ZA200707930B/en unknown
- 2007-10-10 IL IL186538A patent/IL186538A0/en not_active IP Right Cessation
- 2007-11-07 NO NO20075662A patent/NO20075662L/no not_active Application Discontinuation
-
2012
- 2012-03-20 IL IL218745A patent/IL218745A0/en unknown
-
2013
- 2013-07-16 JP JP2013147501A patent/JP2013237683A/ja active Pending
- 2013-10-09 CY CY20131100878T patent/CY1114468T1/el unknown
- 2013-10-16 HR HRP20130982TT patent/HRP20130982T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20130982T1 (hr) | Roflumilast za lijeäśenje pulmonalne hipertenzije | |
| CY1107498T1 (el) | Φαρμακευτικη συνθεση πepιλαμβανουσα ρεσβepατρολη για την αγωγη φλεγμονωδων αναπνευστικων διαταραχων | |
| HRP20170624T1 (hr) | Derivat piridina i pirazina za liječenje kronične opstrukcijske plućne bolesti | |
| HRP20050570A2 (en) | Powdered medicament for inhalation comprising a tiotropium salt and salmetrol xinafoate | |
| JP2008518090A5 (hr) | ||
| CY1111133T1 (el) | Υπερλεπτο σκευασμα φορμοτερολης | |
| JP2013231087A5 (hr) | ||
| BR0008699A (pt) | Combinações de formoterol e furoato demometasona para asma | |
| CA2550841A1 (en) | Novel combination of anticholinergic and .beta. mimetics for the treatment of respiratory diseases | |
| HRP20221325T1 (hr) | Pripravci i postupci transmukozne apsorpcije | |
| JP2008510714A5 (hr) | ||
| RS52867B (en) | GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS | |
| WO2009112274A3 (en) | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease | |
| JP2009503104A5 (hr) | ||
| BRPI0409962A (pt) | co-formulação particulada de uma substáncia ativa e um excipiente, composição farmacêutica ou nutricêutrica, produto farmacêutico ou nutricêutico, método para preparar uma co-formulação particulada de uma substáncia ativa e um excipiente, e, uso de uma substáncia ativa e um excipiente | |
| WO2007112274A3 (en) | Formulations of low dose non-steroidal anti-inflammatory drugs and beta-cyclodextrin | |
| BRPI0806392A8 (pt) | uso de aclidínio, aclidínio, método de tratamento ou prevenção e composição farmacêutica | |
| BR0309115A (pt) | Composição farmacêutica em pó seco, método de tratamento ou profilaxia de distúrbios respiratórios, uso de uma composição farmacêutica em pó seco, dispositivo de inalação, embalagem de medicamento, e, uso de carboidratos derivados particulados em composição farmacêutica em pó seco | |
| JP2008502699A5 (hr) | ||
| WO2008075320A3 (en) | Antilipidemic pharmaceutical compositions and process for preparation thereof | |
| JP2015511625A5 (hr) | ||
| JP2008536888A5 (hr) | ||
| BR0309114A (pt) | Uso de carboidratos derivados particulados em composições farmacêuticas em pó seco, composição farmacêutica em pó seco para terapia de inalação, método de tratamento ou profilaxia de distúrbios respiratórios, uso de uma composição farmacêutica em pó seco, dispositivo de inalação, e, embalagem de medicamento | |
| JP2009534367A5 (hr) | ||
| BRPI0410374A (pt) | composição farmacêutica que compreende valsartano |